Drug class: Interleukin-17A antagonist (1) Mechanism of Action Secukinumab is a targeted biologic therapy designed to interrupt key pathways in inflammatory diseases. It works by binding to interleukin 17A (IL 17A), a cytokine central to the inflammatory process. By blocking IL 17A from interacting with its receptor on keratinocytes and other cell types, secukinumab neutralizes this signaling pathway. This inhibition reduces the downstream inflammatory cascade that drives pla